BOPA guidelines for biosimilars: a new era in biological therapy
This latest expert view from Andrew Roberts considers the scenario for biosimilars in the UK. Mr Roberts is director of market access at Napp Pharmaceuticals and vice chairman of the British Biosimilars Association (BBA). Napp Pharmaceuticals provides Truxima (biosimilar rituximab) in the UK and was also responsible for bringing Remsima (biosimilar infliximab) to the UK market in 2015.
The first quarter of 2017 has hailed a fresh approach to the commissioning of biological medicines in the field of oncology.
Biosimilar medicines represent a significant opportunity that may allow the financially burdened National Health Service (NHS) to release savings in this specialized and costly area of healthcare.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze